SUO 2017
Annual Meeting at the AUA
Saturday, May 13, 2017
8:00 a.m. to 5:00 p.m.
Westin Boston Waterfront
Boston, Massachusetts
SUO 2017 Annual Meeting at the AUA
Saturday, May 13, 2017
Westin Boston Waterfront – Grand Ballroom,
Concourse Level
8:00 a.m. to 5:00 p.m.
Boston, Massachusetts

The morning session is a combined meeting of the Society of Urologic Oncology (SUO) and the Society of Basic Urologic Research (SBUR).

SUO/SBUR: Big Data and Precision Medicine
8:00 a.m. – 11:55 a.m.

8:00 a.m. – 8:05 a.m. Welcome and Introduction

8:05 a.m. – 9:20 a.m. Big Data in Prostate Cancer
Moderators: Ganesh V. Raj, MD, PhD
Christopher P. Evans, MD, FACS

8:05 a.m. – 8:25 a.m. Identifying Cancer Vulnerabilities Through Personalized Network Identification
Speaker: Joshua Stuart, PhD

8:25 a.m. – 8:45 a.m. DNA Repair Pathways in Metastatic Therapy Resistant Cancer
Speaker: Peter Nelson, MD

8:45 a.m. – 9:05 a.m. Translating Big Data in Prostate Cancer to the Clinic
Speaker: Scott Tomlins, MD, PhD

9:05 a.m. – 9:20 a.m. Panel Discussion and Questions

9:20 a.m. – 9:25 a.m. Introduction: Opportunities and Challenges Associated with Big Data
Moderators: Christopher Barbieri, PhD, MD
Hannelore Heemers, PhD

9:25 a.m. – 9:45 a.m. Leveraging the Power of Ultra-Deep Sequencing
Speaker: Colin Collins II, PhD

9:45 a.m. – 10:05 a.m. Studying Niche Populations: Neuroendocrine Prostate Cancers
Speaker: Himisha Beltran, MD

10:05 a.m. – 10:25 a.m. Creating an Institution-Wide Systems Biology Initiative
Speaker: David B. Soll, MD

10:25 a.m. – 10:45 a.m. Genome Drivers of Response to Existing and Emerging Therapies in Bladder Cancer
Speaker: Eliezer Van Allen, MD

10:45 a.m. – 11:00 a.m. Panel Discussions and Questions

11:00 a.m. – 11:05 a.m. Donald S. Coffey Lecture Introduction
Speaker: Ganesh V. Raj, MD, PhD

11:05 a.m. – 11:45 a.m. Donald S. Coffey Lecture: Broad Big Data and Beyond
Speaker: Levi Garraway, MD, PhD

Levi Garraway, MD, PhD is a Dana-Farber Cancer Institute assistant professor of medicine, Broad Institute senior associate member, and Foundation Medicine founding advisor. He is a leading expert in cancer genomics and focuses on melanoma and prostate cancer. Dr. Garraway graduated from Harvard Medical School.

11:45 a.m. – 11:55 a.m. Questions

11:55 a.m. Adjourn

SUO: Novel Management Approaches
12:30 p.m. – 5:00 p.m.

12:30 p.m. – 12:40 p.m. State of Affairs of the SUO
President: Leonard G. Gomella, MD, FACS
President-Elect: Christopher P. Evans, MD

12:40 p.m. – 12:45 p.m. Welcome and Introductions
Program Chairs: Scott E. Eggener, MD
James M. McKiernan, MD

12:45 p.m. – 12:55 p.m. Introduction to the Whitmore Lecture
Speaker: Leonard G. Gomella, MD, FACS

12:55 p.m. – 1:15 p.m. Whitmore Lecture: Triage to SPORE – The Variable Slope of Success and How Opportunity Manifests
Speaker: Colin P. N. Dinney, MD

Colin P. N. Dinney, MD is the MD Anderson Cancer Center department of urology chairman and department of surgery professor. He has received numerous awards and made significant contributions through his work on immunotherapy of renal cell carcinoma with lipoproteins, metastasis bladder cancer, and early and advanced bladder cancer therapy. Dr. Dinney maintains an active clinical practice and research laboratory.

1:15 p.m. – 2:30 p.m. Prostate Cancer: Screening and Diagnostic Biomarkers
Session Chair: Peter Carroll, MD, MPH

1:15 p.m. – 1:25 p.m. Best Prostate Cancer Papers from the Past Year
Speaker: Mark Preston, MD

1:25 p.m. – 1:40 p.m. Genetic Testing in Inherited Prostate Cancer Risk: Consensus Statement
Speaker: Veda Giri, MD

1:40 p.m. – 1:55 p.m. Reflex Testing with Serum, Urine, and Tissue Biomarkers - Which, When, and How Valuable?
Speaker: Stacy Loeb, MD
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Panelists</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:55 p.m. – 2:10 p.m.</td>
<td>Multiparametric MRI – When, Who, and How to Interpret?</td>
<td>Moderator: Peter R. Carroll, MD, MPH European Perspective: Caroline Moore, MD US Perspective: Peter Pinto, MD</td>
</tr>
<tr>
<td>2:10 p.m. – 2:30 p.m.</td>
<td>How I Screen – Panel</td>
<td>EAU View: Nicolas Mottet, MD NCCN View: J. K. Parsons, MD, MHS AUA View: Herbert B. Carter, MD Asia View: Kazuto Ito, MD</td>
</tr>
<tr>
<td>2:30 p.m. – 2:40 p.m.</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>2:40 p.m. – 2:45 p.m.</td>
<td>SUO &amp; AUA Prostate Cancer Foundation Award</td>
<td>Speaker: Stuart Holden, MD</td>
</tr>
<tr>
<td>2:45 p.m. – 2:50 p.m.</td>
<td>SUO Awards</td>
<td>President: Leonard G. Gomella, MD, FACS</td>
</tr>
<tr>
<td>2:50 p.m. – 4:10 p.m.</td>
<td>Bladder Cancer: Novel Treatment for Today and the Future</td>
<td>Session Chair: Sam Chang, MD, MBA</td>
</tr>
<tr>
<td>2:50 p.m. – 2:58 p.m.</td>
<td>Best Urothelial Cancer Papers from 2016</td>
<td>Speaker: Anne Schuckman, MD</td>
</tr>
<tr>
<td>2:58 p.m. – 3:06 p.m.</td>
<td>Beyond Cytology: What is the Urinary Marker We Should Use Now and What Will Be the Best in the Future?</td>
<td>Speaker: Kristen Scarpatto, MD, MPH</td>
</tr>
<tr>
<td>3:06 p.m. – 3:14 p.m.</td>
<td>What is the Best Imaging and What Will We be Using in the Future: Cystoscopy and Cross Sectional Imaging?</td>
<td>Speaker: Joseph Liao, MD</td>
</tr>
<tr>
<td>3:14 p.m. – 3:26 p.m.</td>
<td>What is Best Systemic Therapy for Metastatic/Invasive Bladder Cancer?</td>
<td>Chemotherapy: Gopa Iyer, MD Immunotherapy/Other: Arjun Balar, MD</td>
</tr>
<tr>
<td>3:26 p.m. – 3:38 p.m.</td>
<td>High Risk Non-Muscle Invasive Bladder Cancer</td>
<td>BCG: Wassim Kassouf, MD BCG and Check Point Inhibitors: Charles Drake, MD, PhD</td>
</tr>
<tr>
<td>3:38 p.m. – 3:50 p.m.</td>
<td>Non-Muscle Invasive Bladder Cancer Guidelines</td>
<td>European Perspective: Maria Ribal, MD, PhD US Perspective: Stephen Boorjian, MD</td>
</tr>
<tr>
<td>3:50 p.m. – 4:10 p.m.</td>
<td>Panel Discussion – Clinical Bladder Cancer Quandaries: What to Do Today and in the Future?</td>
<td>Moderator: Sam Chang, MD, MBA Panelists: Cheryl Lee, MD Juan Palou, MD, PhD Wade Sexton, MD Gary Steinberg, MD</td>
</tr>
<tr>
<td>4:10 p.m. – 5:00 p.m.</td>
<td>Kidney Cancer: Accurate Diagnosis and Targeted Treatment</td>
<td>Session Chair: Antonio Finelli, MD</td>
</tr>
<tr>
<td>4:10 p.m. – 4:20 p.m.</td>
<td>Best Kidney Cancer Papers from Past Year</td>
<td>Speaker: Alex Kutikov, MD, FACS</td>
</tr>
<tr>
<td>4:20 p.m. – 4:30 p.m.</td>
<td>Role of Biopsy in the Management of Small Renal Masses</td>
<td>Speaker: Tracey Krupski, MD, MPH</td>
</tr>
<tr>
<td>4:30 p.m. – 4:40 p.m.</td>
<td>Cystic Renal Masses: Radiographic Assessment and Management</td>
<td>Speaker: Vincenzo Ficarra, MD, FEBU</td>
</tr>
<tr>
<td>4:40 p.m. – 4:50 p.m.</td>
<td>The Role of Neoadjuvant and Adjuvant Systemic Therapy in RCC</td>
<td>Speaker: Mohammad Allaf, MD</td>
</tr>
<tr>
<td>4:50 p.m. – 5:00 p.m.</td>
<td>The Reemergence of Immunotherapy in RCC and Novel Clinical Trials</td>
<td>Speaker: Lauren Harshman, MD</td>
</tr>
<tr>
<td>5:00 p.m.</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

YOU'RE INVITED!

Immediately following the afternoon session on Saturday, May 13, will be a networking and socializing reception co-sponsored by the SUO and Young Urologic Oncologists (Y.U.O.). The reception will be next door to the general session in the Commonwealth Ballroom. Doors will open at 5:00 p.m. Seasoned urologic oncologists as well as residents, fellows, and medical students are welcome to attend.

SUO/Y.U.O. Reception
Westin Boston Waterfront
Commonwealth Ballroom
5:00 p.m. – 7:00 p.m.
Business Attire
SUO/SBUR Joint Meeting Educational Needs (Morning Program)

The rapid emergence of Big Data and its adoption in clinical decision making has created an educational need for this forum to enable urologic oncologists to rapidly understand the analyses and interpretation of Big Data. Since these Big Data projects are likely to be rapidly integrated into clinical practice, this forum is critical for urologic oncologists, urologists, and basic scientists alike.

SUO/SBUR Educational Objectives (Morning Program)

At the conclusion of the SBUR/SUO morning session at the AUA 2017 Annual Meeting, attendees should be able to:

- Explain the current status of Big Data in Urologic Oncology.
- Describe how the combination of data analytics and decision-making processes has the potential to guide precision medicine.
- Explain how Big Data can enable value based care.
- Identify the limitations and challenges associated with Big Data.

SUO Annual Meeting at the AUA Educational Needs (Afternoon Program)

The inability to accurately determine who should undergo primary or secondary prostate biopsy in the era of MRI and serum and urine biomarker testing creates an educational unmet need. Following a diagnosis of prostate cancer, determining the extent of disease and improving upon the risk characterization afforded by clinical parameters is an unmet educational need. Ultimately determining risk of relapse following intervention and accurately offering adjuvant and salvage therapies is an unmet educational need as well. Taken together, these needs represent the ultimate knowledge gap in men with localized prostate cancer and those at risk for this disease. These issues of screening, diagnostic, and therapeutic dilemmas affect over 2,000,000 men every year in the United States. Improving upon the practicing urologic oncologist’s ability to accurately sort through this information will have a direct impact on patient care and outcomes in 2017.

The ability to improve upon the success rate in the treatment of non-muscle invasive bladder cancer has led to an unmet educational need. The topic of how we add to the foundation of BCG immunotherapy is an area of unmet educational need that must be addressed. In addition, the use and timing of perioperative systemic chemotherapy and how to increase its utilization in America is a critical educational need. An improved understanding of emerging predictive biomarkers to help select patients at risk of resistance or response to the therapies is also needed. The addition of systemic checkpoint inhibition to these regimens is also an area that requires further exploration. The clinical competency of performing extended lymph node dissection and the educational awareness of its role in the proper management of muscle invasive bladder cancer is a significant unmet medical need in the field of bladder cancer.

The role of percutaneous renal biopsy and how to integrate this technique into routine clinical practice is an area of knowledge gap that requires education. Since no standard battery of biomarkers has been agreed upon in renal cancer, a thorough understanding of all developing biomarkers and indications for percutaneous biopsy are educational necessities. Emerging strategies to improve upon the outcomes of patients with non-metastatic high risk renal cancer requires further education and exploration as well. In addition, the pathways involved in the development of the next generation of effective targeted therapies as well as the checkpoint inhibitors is a critical unmet educational need.

SUO Annual Meeting at the AUA Educational Objectives (Afternoon Program)

As a result of attending this conference, it would be expected the learner will take away several key areas of new clinical knowledge that will be instrumental in their daily management of patients with prostate, bladder, and kidney cancer.

Prostate Cancer

- Describe the role of multiparametric MRI scanning in the primary and secondary screening of patients with risk of prostate cancer.
- Integrate serum PSA derivatives, urinary exosomal RNA testing, and routine clinical parameters into the decision of when to perform both primary as well as secondary prostate biopsy.
- Interpret and utilize tissue based genomic testing to further characterize prostate cancer risk features in an effort to provide better personalized treatment recommendations.
- Create individualized postoperative treatment recommendations to prevent recurrence for patients with high risk feature using proteomic and genomic tissue markers.

Bladder Cancer

- Explain the emerging studies of BCG therapy in combination with other agents such as other immunotherapies as well as chemotherapy.
- Customize treatment recommendations in the use of perioperative chemotherapy in muscle invasive bladder cancer as well as understand the biomarkers involved in predicting response and resistance. Integrate checkpoint inhibitor emerging data into the paradigm of systemic therapy for muscle invasive bladder cancer.
- Indicate how to handle those patients that exhibit a complete response to systemic chemotherapy for non-metastatic muscle invasive bladder cancer.
- Explain the risks and benefits of standard and extended lymph node dissection in the treatment of muscle invasive bladder cancer and who may benefit from each technique.

Kidney Cancer

- Integrate percutaneous renal mass biopsy into a pathway of management for patients with renal masses.
- Develop an understanding of biomarkers to predict risk in patients with renal cancer.
- Identify the challenges to effective systemic adjuvant therapy for patients with high risk resected renal cancer.
- Explain the options for targeted and checkpoint inhibitor therapy of metastatic renal cell cancer and a strategy to select tailored therapies for individual patients.

AUA ACCREDITATION INFORMATION

SUO/SBUR Joint Meeting Accreditation (Morning Program)

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
SUO Annual Meeting at the AUA Accreditation (Afternoon Program)

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this activity for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-physician Health Professionals: The AUA is not accredited to offer credit for non-physician health professionals. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.

Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer: The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA’s use and distribution (both now and in the future) of the attendee’s image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video, and Photographic Equipment: The use of audio, video, and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The American Urological Association complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

SUBMIT YOUR ABSTRACT FOR THE 18TH ANNUAL MEETING

Abstract submissions are open Friday, May 12, 2017 through Tuesday, August 15, 2017

Online only at www.suonet.org
THANK YOU TO THE SUO 2016 - 2017 CORPORATE PARTNERS

Astellas and Pfizer Oncology
AstraZeneca
Genentech
Genomic Health
Janssen Biotech
Myriad Genetic Laboratories

REGISTRATION OPEN

18th Annual SUO Winter Meeting
Wednesday, November 29 - Friday, December 1, 2017

Y.U.O. Dinner: Wednesday, November 29
SUO Reception: Thursday, November 30

Renaissance Washington DC Downtown Hotel
999 9th St | Washington, DC 20001 | Phone: (202) 898-9000

SUO is happy to provide a discounted room rate of $243.00, plus applicable tax, at the host hotel. The block may sell out prior to the hotel deadline of November 4, 2017; therefore, attendees are strongly encouraged to make early reservations.

Visit our website at www.suonet.org for updates on the program agenda and meeting registration.